The main biomarkers used in the differential diagnostics of neurodegenerative disorders, in particular Alzheimer’s disease, are the levels of beta-amyloids and tau proteins in the cerebrospinal fluid of patients [9]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.